Nextcure, INC Schedule 13G passive stakes

ADAR1 Capital Management, LLC and Daniel Schneeberger have filed a joint Schedule 13G statement regarding their beneficial ownership of NextCure, Inc. common stock.

Ikarian Capital, LLC and Neil Shahrestani have filed a Schedule 13G, reporting beneficial ownership of 9.99% of NextCure, Inc.'s common stock, including potential shares from warrants.

Squadron Master Fund LP, along with affiliated entities and individuals, has reported beneficial ownership of approximately 1.6% of NextCure, Inc.'s common stock.

Adage Capital Management, L.P. and its affiliates have reported beneficial ownership of 7.67% of NextCure, Inc.'s common stock as of June 30, 2026.

SilverArc Capital Management, LLC and Devesh Gandhi have reported beneficial ownership of 4.9% of NextCure, Inc.'s Class A Common Stock as of March 31, 2026.

Simcere Pharmaceutical Group and its affiliates have disclosed a significant 9.4% passive ownership stake in NextCure, Inc., totaling 338,636 shares.

Squadron Master Fund LP and affiliated entities have disclosed a 9.99% beneficial ownership stake in NextCure, Inc. as of December 31, 2025.

Pfizer Inc. and its affiliate Pfizer Ventures (US) LLC have reported a combined beneficial ownership of 3.0% in NEXTCURE, INC. common stock.

SilverArc Capital Management and Devesh Gandhi have reported a 5.02% beneficial ownership stake in NextCure, Inc.'s Class A Common Stock.

Affinity Asset Advisors and Michael Cho have disclosed a 9.99% beneficial ownership stake in NextCure, Inc., including shares from warrants.

Affinity Healthcare Fund, LP and Affinity Asset Advisors, LLC have disclosed a 7.17% beneficial ownership stake in NextCure, Inc., totaling 191,882 common shares.

Squadron Master Fund LP and related entities have disclosed beneficial ownership of 6.5% of NextCure, Inc.'s common stock.

A group of Simcere-affiliated entities and individuals have disclosed a 12.7% beneficial ownership stake in NextCure, Inc. through a Schedule 13G filing.

Citigroup Global Markets Inc. and its affiliates have disclosed a passive beneficial ownership of 4.3% of Nextcure, Inc.'s common stock as of March 31, 2025.

Logos Global Management LP and its affiliated entities have filed an amended Schedule 13G, disclosing that they no longer hold any beneficial ownership in NextCure, Inc. as of December 31, 2024.